GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Cyclically Adjusted Revenue per Share

Inotiv (STU:BS50) Cyclically Adjusted Revenue per Share : €8.33 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inotiv Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Inotiv's adjusted revenue per share for the three months ended in Mar. 2024 was €4.240. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.33 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Inotiv's average Cyclically Adjusted Revenue Growth Rate was 28.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 28.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Inotiv was 28.50% per year. The lowest was -12.40% per year. And the median was -3.30% per year.

As of today (2024-05-24), Inotiv's current stock price is €1.82. Inotiv's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €8.33. Inotiv's Cyclically Adjusted PS Ratio of today is 0.22.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inotiv was 14.19. The lowest was 0.11. And the median was 0.39.


Inotiv Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Inotiv's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Cyclically Adjusted Revenue per Share Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 7.81

Inotiv Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.58 7.26 7.81 7.91 8.33

Competitive Comparison of Inotiv's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Inotiv's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inotiv's Cyclically Adjusted PS Ratio falls into.



Inotiv Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inotiv's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.24/131.7762*131.7762
=4.240

Current CPI (Mar. 2024) = 131.7762.

Inotiv Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.493 100.560 0.646
201409 0.617 100.428 0.810
201412 0.494 99.070 0.657
201503 0.653 99.621 0.864
201506 0.622 100.684 0.814
201509 0.514 100.392 0.675
201512 0.554 99.792 0.732
201603 0.591 100.470 0.775
201606 0.555 101.688 0.719
201609 0.566 101.861 0.732
201612 0.673 101.863 0.871
201703 0.683 102.862 0.875
201706 0.594 103.349 0.757
201709 0.562 104.136 0.711
201712 0.517 104.011 0.655
201803 0.549 105.290 0.687
201806 0.625 106.317 0.775
201809 0.750 106.507 0.928
201812 0.740 105.998 0.920
201903 0.804 107.251 0.988
201906 0.916 108.070 1.117
201909 1.278 108.329 1.555
201912 1.090 108.420 1.325
202003 1.336 108.902 1.617
202006 1.283 108.767 1.554
202009 1.219 109.815 1.463
202012 1.335 109.897 1.601
202103 1.413 111.754 1.666
202106 1.235 114.631 1.420
202109 1.539 115.734 1.752
202112 3.528 117.630 3.952
202203 5.033 121.301 5.468
202206 6.403 125.017 6.749
202209 5.936 125.227 6.246
202212 4.526 125.222 4.763
202303 5.507 127.348 5.699
202306 5.586 128.729 5.718
202309 5.173 129.860 5.249
202312 4.823 129.419 4.911
202403 4.240 131.776 4.240

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Inotiv  (STU:BS50) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Inotiv's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.82/8.33
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inotiv was 14.19. The lowest was 0.11. And the median was 0.39.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Inotiv Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Inotiv's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (STU:BS50) Business Description

Industry
Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines